Unicycive Therapeutics (UNCY) Competitors

Aura Biosciences (NASDAQ:AURA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Does the media favor AURA or UNCY?

In the previous week, Unicycive Therapeutics had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Unicycive Therapeutics' score of 0.78 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Very Positive
Unicycive Therapeutics	Positive

Which has more volatility & risk, AURA or UNCY?

Aura Biosciences has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of AURA or UNCY?

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer AURA or UNCY?

Aura Biosciences currently has a consensus price target of $22.00, indicating a potential upside of 227.87%. Unicycive Therapeutics has a consensus price target of $6.00, indicating a potential upside of 837.50%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Unicycive Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50

Which has higher earnings and valuation, AURA or UNCY?

Unicycive Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$76.41M	-$1.90	-3.53
Unicycive Therapeutics	$680K	113.53	-$30.54M	-$0.51	-1.25

Is AURA or UNCY more profitable?

Unicycive Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-41.57%	-36.43%
Unicycive Therapeutics	N/A	N/A	-29.88%

Does the MarketBeat Community believe in AURA or UNCY?

Unicycive Therapeutics received 8 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 78.26% of users gave Unicycive Therapeutics an outperform vote while only 63.64% of users gave Aura Biosciences an outperform vote.

Company	Underperform	Outperform
Aura Biosciences	Outperform Votes 28 63.64%	Underperform Votes 16 36.36%
Unicycive Therapeutics	Outperform Votes 36 78.26%	Underperform Votes 10 21.74%

Summary

Unicycive Therapeutics beats Aura Biosciences on 13 of the 16 factors compared between the two stocks.